GoodRx reported Q4 2025 revenue of USD 194.8 million, net income of USD 5.4 million (2.8% margin) and adjusted EBITDA of USD 65.0 million (33.4% margin). For FY 2025, revenue was USD 796.9 million (up 1%), net income was USD 30.4 million (3.8% margin) and adjusted EBITDA was USD 270.5 million (33.9% margin). FY 2025 prescription transactions revenue was USD 544.0 million (down 6%), subscription revenue was USD 83.8 million (down 3%), and Pharma Direct revenue rose to USD 151.4 million (up 41%), following the rebrand of Pharma Manufacturer Solutions to Pharma Direct. GoodRx said it expanded manufacturer partnerships, grew differentiated subscription offerings and strengthened retail relationships, while noting broader changes in the retail pharmacy landscape, including store closures, affected Monthly Active Consumers, which averaged 5.3 million in Q4 2025. In FY 2025, the company repurchased 48.9 million shares for USD 217.4 million and ended 2025 with USD 261.8 million in cash and cash equivalents and USD 495.0 million of total outstanding debt. For FY 2026, GoodRx guided revenue of USD 750 million to USD 780 million and adjusted EBITDA of more than USD 230 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602251605BIZWIRE_USPR_____20260225_BW769868) on February 25, 2026, and is solely responsible for the information contained therein.